FDA — authorised 12 February 1952
- Application: ANDA060111
- Marketing authorisation holder: PFIZER
- Local brand name: STREPTOMYCIN SULFATE
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 STREPTOMYCIN SULFATE in United States
FDA authorised STREPTOMYCIN SULFATE on 12 February 1952
Marketing authorisations
FDA — authorised 30 June 1998
- Application: ANDA064210
- Marketing authorisation holder: XGEN PHARMS
- Local brand name: STREPTOMYCIN SULFATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Status: approved
FDA
- Application: ANDA060404
- Marketing authorisation holder: LILLY
- Local brand name: STREPTOMYCIN SULFATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA060107
- Marketing authorisation holder: LILLY
- Local brand name: STREPTOMYCIN SULFATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA060684
- Marketing authorisation holder: COPANOS
- Local brand name: STREPTOMYCIN SULFATE
- Indication: INJECTABLE — INJECTION
- Status: approved
STREPTOMYCIN SULFATE in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is STREPTOMYCIN SULFATE approved in United States?
Yes. FDA authorised it on 12 February 1952; FDA authorised it on 30 June 1998; FDA has authorised it.
Who is the marketing authorisation holder for STREPTOMYCIN SULFATE in United States?
PFIZER holds the US marketing authorisation.